This Medudy course is a video tutorial for physicians on the topic of "Enzalutamide in biochemically recurrent prostate cancer". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Patients with prostate cancer who have a high risk of biochemical recurrence have an increased risk of progression. This phase 3 study investigated the efficacy and safety of enzalutamide in combination with ADT therapy and enzalutamide monotherapy compared to ADT therapy alone.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this training course you will know:
- the clinical background and relevance of the research question investigated
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
